133 related articles for article (PubMed ID: 9797033)
21. Contralateral, ipsilateral and bilateral treatments with the kappa-opioid receptor agonist U-50,488H in mononeuropathic rats.
Bileviciute-Ljungar I; Spetea M
Eur J Pharmacol; 2004 Jun; 494(2-3):139-46. PubMed ID: 15212967
[TBL] [Abstract][Full Text] [Related]
22. Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of kappa opioid receptor multiplicity in mice.
Horan P; de Costa BR; Rice KC; Porreca F
J Pharmacol Exp Ther; 1991 Jun; 257(3):1154-61. PubMed ID: 1646325
[TBL] [Abstract][Full Text] [Related]
23. Naltrexone in vivo protects mu receptors from inactivation by beta-funaltrexamine, but not kappa receptors from inactivation by nor-binaltorphimine.
Paronis CA; Waddell AB; Holtzman SG
Pharmacol Biochem Behav; 1993 Dec; 46(4):813-7. PubMed ID: 8309960
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of specific delta and kappa opioid receptor antagonists on the bidirectional dose-dependent effect of systemic naloxone in arthritic rats, an experimental model of persistent pain.
Cattaneo I; Kayser V; Guilbaud G
Brain Res; 1993 Oct; 623(2):201-7. PubMed ID: 8221101
[TBL] [Abstract][Full Text] [Related]
25. Opioid systems in the response to inflammatory pain: sustained blockade suggests role of kappa- but not mu-opioid receptors in the modulation of nociception, behaviour and pathology.
Millan MJ; Colpaert FC
Neuroscience; 1991; 42(2):541-53. PubMed ID: 1654538
[TBL] [Abstract][Full Text] [Related]
26. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
[TBL] [Abstract][Full Text] [Related]
27. Antinociceptive actions of dexmedetomidine and the kappa-opioid agonist U-50,488H against noxious thermal, mechanical and inflammatory stimuli.
Idänpään-Heikkilä JJ; Kalso EA; Seppälä T
J Pharmacol Exp Ther; 1994 Dec; 271(3):1306-13. PubMed ID: 7996439
[TBL] [Abstract][Full Text] [Related]
28. Putative kappa-2 opioid agonists are antihyperalgesic in a rat model of inflammation.
Ho J; Mannes AJ; Dubner R; Caudle RM
J Pharmacol Exp Ther; 1997 Apr; 281(1):136-41. PubMed ID: 9103490
[TBL] [Abstract][Full Text] [Related]
29. delta-opioid receptors and nitric oxide mediate the analgesic effect of Crotalus durissus terrificus snake venom.
Picolo G; Giorgi R; Cury Y
Eur J Pharmacol; 2000 Mar; 391(1-2):55-62. PubMed ID: 10720635
[TBL] [Abstract][Full Text] [Related]
30. Role of vagal afferents in the antinociception produced by morphine and U-50,488H in the colonic pain reflex in rats.
Diop L; Rivière PJ; Pascaud X; Dassaud M; Junien JL
Eur J Pharmacol; 1994 May; 257(1-2):181-7. PubMed ID: 8082700
[TBL] [Abstract][Full Text] [Related]
31. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
Wilson JL; Nayanar V; Walker JS
Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
[TBL] [Abstract][Full Text] [Related]
32. Activation of micro, delta or kappa opioid receptors by DAMGO, DPDPE, U-50488 or U-69593 respectively causes antinociception in the formalin test in the naked mole-rat (Heterocephalus glaber).
Towett PK; Kanui TI; Maloiy GM; Juma F; Olongida Ole Miaron J
Pharmacol Biochem Behav; 2009 Feb; 91(4):566-72. PubMed ID: 18929596
[TBL] [Abstract][Full Text] [Related]
33. Estrogen and progesterone activate spinal kappa-opiate receptor analgesic mechanisms.
Dawson-Basoa ME; Gintzler AR
Pain; 1996 Jan; 64(1):169-177. PubMed ID: 8867260
[TBL] [Abstract][Full Text] [Related]
34. GR94839, a kappa-opioid agonist with limited access to the central nervous system, has antinociceptive activity.
Rogers H; Birch PJ; Harrison SM; Palmer E; Manchee GR; Judd DB; Naylor A; Scopes DI; Hayes AG
Br J Pharmacol; 1992 Aug; 106(4):783-9. PubMed ID: 1327387
[TBL] [Abstract][Full Text] [Related]
35. Study of the involvement of K+ channels in the peripheral antinociception of the kappa-opioid receptor agonist bremazocine.
Amarante LH; Alves DP; Duarte ID
Eur J Pharmacol; 2004 Jun; 494(2-3):155-60. PubMed ID: 15212969
[TBL] [Abstract][Full Text] [Related]
36. The use of specific opioid agonists and antagonists to delineate the vagally mediated antinociceptive and cardiovascular effects of intravenous morphine.
Randich A; Robertson JD; Willingham T
Brain Res; 1993 Feb; 603(2):186-200. PubMed ID: 8096421
[TBL] [Abstract][Full Text] [Related]
37. The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons.
Chieng B; Connor M; Christie MJ
Mol Pharmacol; 1996 Sep; 50(3):650-5. PubMed ID: 8794906
[TBL] [Abstract][Full Text] [Related]
38. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
Millan MJ; Członkowski A; Lipkowski A; Herz A
J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats.
Steinmiller CL; Young AM
Psychopharmacology (Berl); 2008 Jan; 195(4):497-507. PubMed ID: 17882404
[TBL] [Abstract][Full Text] [Related]
40. Profiles of the antinociceptive effect of R-84760, a selective kappa-opioid receptor agonist, in the formalin test in mice.
Fujibayashi K; Iizuka Y
Jpn J Pharmacol; 1995 May; 68(1):57-63. PubMed ID: 7494383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
